| __timestamp | Corcept Therapeutics Incorporated | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 59644696 |
| Thursday, January 1, 2015 | 36949000 | 79541000 |
| Friday, January 1, 2016 | 45240000 | 98015000 |
| Sunday, January 1, 2017 | 62416000 | 103958000 |
| Monday, January 1, 2018 | 81289000 | 103654000 |
| Tuesday, January 1, 2019 | 100359000 | 128951000 |
| Wednesday, January 1, 2020 | 105326000 | 135799000 |
| Friday, January 1, 2021 | 122356000 | 149883000 |
| Saturday, January 1, 2022 | 152848000 | 220206000 |
| Sunday, January 1, 2023 | 184259000 | 265542000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Corcept Therapeutics Incorporated and Travere Therapeutics, Inc. have shown distinct trajectories in their SG&A spending.
From 2014 to 2023, Corcept's SG&A expenses have grown steadily, increasing by over 400%. This growth reflects their strategic investments in expanding operations and market reach. By 2023, their SG&A expenses reached approximately 184 million, showcasing a consistent upward trend.
Travere, on the other hand, has experienced a more dramatic rise, with SG&A expenses surging by nearly 345% over the same period. By 2023, their expenses peaked at around 266 million, indicating aggressive expansion and market penetration strategies.
Both companies demonstrate unique approaches to managing SG&A expenses, reflecting their strategic priorities in the evolving pharmaceutical sector.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Alkermes plc vs Travere Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Travere Therapeutics, Inc. and Celldex Therapeutics, Inc.